

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weyto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/790,730	03/03/2004	Makoto Ozeki	1422-0625P	2621	
2292 BIRCH STEW	7590 07/16/200 ART KOLASCH & BI	EXAM	EXAMINER		
PO BOX 747			CLAYTOR, DE	CLAYTOR, DEIRDRE RENEE	
FALLS CHUF	RCH, VA 22040-0747		ART UNIT	PAPER NUMBER	
		1617			
			NOTIFICATION DATE	DELIVERY MODE	
			07/16/2008	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail $\,$ address(es):

mailroom@bskb.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/790,730	OZEKI ET AL.		
Examiner	Art Unit		
Renee Claytor	1617		

	Renee Claytor	1617						
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress					
THE REPLY FILED 16 June 2008 FAILS TO PLACE THIS APP	PLICATION IN CONDITION FOR A	LLOWANCE.						
 The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of App 	The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of the application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Reques for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time							
a) The period for reply expires months from the mailing	date of the final rejection.							
no event, however, will the statutory period for reply expire I Examiner Note: If box 1 is checked, check either box (a) or	The period for reply expires on: (1) the mailing date of his Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b), ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TW MONTHS OF THE FINAL REJECTION. See MPEP 766 07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension is under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action, or (2) set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filler may reduce any earned patent term adjustment. See 37 CFR 1.704 in the contract of the final contract of the final rejection of the final rejection.								
NOTICE OF APPEAL 2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte Notice of Appeal has been filed, any reply must be filed w	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the						
AMENDMENTS								
 The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE beld (c) They are not deemed to place the application in bet 	nsideration and/or search (see NOTow);	E below);						
appeal; and/or (d) They present additional claims without canceling a	corresponding number of finally reje	ected claims.						
NOTE: (See 37 CFR 1.116 and 41.33(a)).								
4. The amendments are not in compliance with 37 CFR 1.1.		mpliant Amendment (i	OL-324).					
 Applicant's reply has overcome the following rejection(s): Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling to non-allowable claim(s). 								
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:	will not be entered, or b) will will will will will will will	be entered and an e	xplanation of					
Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: <u>5 and 7-11</u> . Claim(s) withdrawn from consideration:								
AFFIDAVIT OR OTHER EVIDENCE								
The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).								
The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to conshowing a good and sufficient reasons why it is necessary.	overcome <u>all</u> rejections under appear y and was not earlier presented. Se	and/or appellant fail ee 37 CFR 41.33(d)(1	s to provide a					
10. The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER		•						
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:								
12. Note the attached Information <i>Disclosure Statement</i> (s). 13. Other:	(PTO/SB/08) Paper No(s)							
/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1617								

Applicant's arguments filed on 6/16/2008 have been fully considered. In particular, Applicants have cancelled claims 4 and 6, which is sufficient to overcome the 35 USC 102(e) rejection. Applicants argue over the 35 USC 103 rejection that Ueda teaches anxiety, which is a distinct symptom from depressed mood. It is however noted that the clinical manifestations and current treatment regiments for depressed mood overlap with those of anxiety (see Goodman & Gilman's, pages 450-451). Therefore, these are two mood disorders that overlap. Accordingly, the rejection is maintained over claims 5 and 7-11.